A Phase 1 study of HMPL-306 in gliomas with IDH1/2 mutations
Recruiting Phase 1 NCT07025018
Study Description
A Phase 1 Study to Evaluate the Safety and Effectiveness of HMPL-306 in Patients with Brain Tumors (Gliomas) Containing IDH1 or IDH2 Mutations
Study Details
- Registry ID:
- NCT07025018
- Conditions:
- Gliomas Harboring IDH1 and/or IDH2 Mutations
- Phase:
- Phase 1
- Target Enrollment:
- 52 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.